BioNTech SE (22UA) - Net Assets
Based on the latest financial reports, BioNTech SE (22UA) has net assets worth €18.48 Billion EUR (≈ $21.60 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€21.34 Billion ≈ $24.95 Billion USD) and total liabilities (€2.86 Billion ≈ $3.35 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 22UA cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €18.48 Billion |
| % of Total Assets | 86.58% |
| Annual Growth Rate | 122.9% |
| 5-Year Change | 1314.96% |
| 10-Year Change | N/A |
| Growth Volatility | 291.13 |
BioNTech SE - Net Assets Trend (2016–2024)
This chart illustrates how BioNTech SE's net assets have evolved over time, based on quarterly financial data. Also explore 22UA total asset value for the complete picture of this company's asset base.
Annual Net Assets for BioNTech SE (2016–2024)
The table below shows the annual net assets of BioNTech SE from 2016 to 2024. For live valuation and market cap data, see 22UA market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €19.41 Billion ≈ $22.69 Billion |
-4.12% |
| 2023-12-31 | €20.25 Billion ≈ $23.67 Billion |
+0.95% |
| 2022-12-31 | €20.06 Billion ≈ $23.45 Billion |
+68.62% |
| 2021-12-31 | €11.89 Billion ≈ $13.90 Billion |
+766.99% |
| 2020-12-31 | €1.37 Billion ≈ $1.60 Billion |
+177.99% |
| 2019-12-31 | €493.49 Million ≈ $576.94 Million |
+84.83% |
| 2018-12-31 | €267.00 Million ≈ $312.15 Million |
+653.87% |
| 2017-12-31 | €-48.21 Million ≈ $-56.36 Million |
-251.32% |
| 2016-12-31 | €31.86 Million ≈ $37.25 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BioNTech SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1921010000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €19.10 Billion | 98.39% |
| Other Components | €313.10 Million | 1.61% |
| Total Equity | €19.41 Billion | 100.00% |
BioNTech SE Competitors by Market Cap
The table below lists competitors of BioNTech SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Reddit, Inc.
NYSE:RDDT
|
$23.25 Billion |
|
Circle Internet Group, Inc.
NYSE:CRCL
|
$23.29 Billion |
|
CMS Energy Corporation
NYSE:CMS
|
$23.30 Billion |
|
ABN Amro Group NV
AS:ABN
|
$23.40 Billion |
|
PulteGroup Inc
NYSE:PHM
|
$23.24 Billion |
|
Epiroc AB (publ)
ST:EPI-A
|
$23.24 Billion |
|
SAIC Motor Corp Ltd
SHG:600104
|
$23.18 Billion |
|
Flex Ltd
NASDAQ:FLEX
|
$23.15 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioNTech SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 20,245,900,000 to 19,411,100,000, a change of -834,800,000 (-4.1%).
- Net loss of 665,300,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-665.30 Million | -3.43% |
| Other Changes | €-169.50 Million | -0.87% |
| Total Change | €- | -4.12% |
Book Value vs Market Value Analysis
This analysis compares BioNTech SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.09x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €-0.21 | €88.25 | x |
| 2018-12-31 | €1.16 | €88.25 | x |
| 2019-12-31 | €2.18 | €88.25 | x |
| 2020-12-31 | €5.68 | €88.25 | x |
| 2021-12-31 | €49.04 | €88.25 | x |
| 2022-12-31 | €82.46 | €88.25 | x |
| 2023-12-31 | €85.16 | €88.25 | x |
| 2024-12-31 | €80.89 | €88.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioNTech SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.18%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.16x
- Recent ROE (-3.43%) is below the historical average (10.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -139.05% | 0.16x | 0.00x | €-80.72 Million |
| 2018 | -18.04% | -37.64% | 0.20x | 2.45x | €-74.63 Million |
| 2019 | -36.28% | -164.89% | 0.14x | 1.62x | €-228.41 Million |
| 2020 | 1.11% | 3.15% | 0.21x | 1.69x | €-121.99 Million |
| 2021 | 86.54% | 54.24% | 1.20x | 1.33x | €9.10 Billion |
| 2022 | 47.04% | 54.50% | 0.74x | 1.16x | €7.43 Billion |
| 2023 | 4.60% | 24.36% | 0.17x | 1.14x | €-1.09 Billion |
| 2024 | -3.43% | -24.18% | 0.12x | 1.16x | €-2.61 Billion |
Industry Comparison
This section compares BioNTech SE's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $964,806,108
- Average return on equity (ROE) among peers: -53.83%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioNTech SE (22UA) | €18.48 Billion | 0.00% | 0.15x | $23.24 Billion |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $209.51 Million | -46.30% | 0.68x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $2.05 Billion |
| Ascletis Pharma Inc (2VJ) | $3.43 Billion | -0.21% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which… Read more